Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Real-time Estimate Cboe Europe  -  11:20 2022-09-30 am EDT
75.50 CHF   +0.77%
09/29Moderna Adds New Role Ahead of Product Launches
DJ
09/28Pm(noc) Regulations : Five-year Anniversary Of Major Amendments
AQ
09/28Europe's generic drugmakers say they may cut output due to energy bills
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis fails again to reuse anti-inflammatory drug to treat lung cancer

08/15/2022 | 04:23am EDT

* Third trial to show desired results in lung cancer

* Anti-inflammatory drug showed oncology potential in 2017

* Analysts still see growth potential in inflammation setting

ZURICH, Aug 15 (Reuters) - Efforts by Novartis to show that an established anti-inflammatory drug could also suppress cancer growth were dealt a final blow when a third big lung cancer trial failed to produce the desired results.

The Swiss drugmaker said on Monday its canakinumab drug did not slow the progression of non-small cell lung cancer in a late-stage trial, when given to prevent relapse in patients that were diagnosed early enough for tumour-removal surgery.

The failure in the latest trial, called Canopy A, is a setback for Novartis after canakinumab failed in two separate studies last year where the drug was tried in combination with other treatments on lung cancer patients at a more advanced disease stage. "Consensus expectations for this high-risk project remained zero or low with the remaining market exclusivity for canakinumab limited until 2028," said Zuercher Kantonalbank analyst Laurent Flamme.

He estimated annual sales of around 300 million Swiss francs ($317.9 million) by 2026 for the drug as an adjuvant treatment for non-small cell lung cancer.

The drug is approved to treat a number of inflammatory disorders under the brand name Ilaris with $284 million in revenues last year. Credit Suisse analysts said annual sales could reach more than $1 billion in that indication.

A cardiovascular disease trial in 2017 produced early indication that the drug might also play a role in preventing lung cancer by suppressing a type of inflammation that drives cancer growth. That prompted Novartis to launch a lung cancer trial programme.

Novartis needs to boost its pharma development efforts as it is conducting a strategic review of its off-patent generic drug business Sandoz that might result in a sale.

It has billions at its disposal for deals to strengthen its research pipeline after selling its 33% stake in Roche back to the Swiss rival last year for $20.7 billion.

($1 = 0.9436 Swiss francs) (Reporting by John Revill in Zurich, Ludwig Burger in Frankfurt; Editing by Emelia Sithole-Matarise and Bernadette Baum)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
CREDIT SUISSE GROUP AG 3.19% 3.951 Delayed Quote.-56.85%
NOVARTIS AG 0.83% 75.5 Delayed Quote.-6.68%
ROCHE HOLDING AG 0.80% 322.8 Delayed Quote.-15.52%
All news about NOVARTIS AG
09/29Moderna Adds New Role Ahead of Product Launches
DJ
09/28Pm(noc) Regulations : Five-year Anniversary Of Major Amendments
AQ
09/28Europe's generic drugmakers say they may cut output due to energy bills
RE
09/28Europe's generic drugmakers may cut output due to surging energy bills
RE
09/27Monsenso participates in new, large innovation project
AQ
09/27Europe's generic drugmakers may cut output due to surging energy bills
RE
09/27Sandoz Granted Leave To Add New Allegations On Condition Of Trial Adjournment And Exten..
AQ
09/26NOVARTIS AG : UBS reiterates its Neutral rating
MD
09/23NOVARTIS AG : Deutsche Bank gives a Sell rating
MD
09/23NOVARTIS AG : Gets a Sell rating from Barclays
MD
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2022 52 278 M - -
Net income 2022 8 970 M - -
Net Debt 2022 7 895 M - -
P/E ratio 2022 18,7x
Yield 2022 4,30%
Capitalization 167 B 167 B -
EV / Sales 2022 3,34x
EV / Sales 2023 3,29x
Nbr of Employees 108 000
Free-Float 87,1%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 25
Last Close Price 76,46 $
Average target price 90,56 $
Spread / Average Target 18,4%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans Jörg Reinhardt Non-Executive Chairman
Shreeram Aradhye Chief Medical Officer
Steffen Lang President-Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-6.68%166 892
JOHNSON & JOHNSON-3.82%432 579
ELI LILLY AND COMPANY21.06%313 567
ROCHE HOLDING AG-15.52%269 089
ABBVIE INC.5.41%252 343
PFIZER, INC.-25.22%247 841